Rare Presentation of Metastatic Endometrioid Adenocarcinoma of Uterus Mimicking as Second Primary in Urinary Bladder on 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography

Other OA: gold publisher-OA-unknown
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-09 ⓘ

This case report describes a rare instance of uterine endometrioid adenocarcinoma metastasis to the bladder mimicking a second primary tumor on 18F-FDG PET/CT, emphasizing the need for histopathology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text ⓘ

This case report describes a 69-year-old postmenopausal woman with painless vaginal bleeding and imaging findings that initially suggested a second primary malignancy in the urinary bladder. Whole-body 18F-FDG PET/CT revealed intense tracer uptake in uterine lesions and bladder wall thickening, leading to a provisional diagnosis of metastatic disease or concurrent cancers. Histopathological examination following transurethral resection of the bladder tumor confirmed the presence of metastatic endometrioid adenocarcinoma originating from the uterus rather than a primary urothelial cancer. The paper highlights the diagnostic challenges posed by rare metastatic presentations on PET/CT and emphasizes the necessity of histopathology for accurate diagnosis. Relevance to endometriosis: mentioned only as a potential mechanism for malignant transformation in the background discussion, while the paper's main focus is uterine endometrial carcinoma.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

We present a case of endometrioid carcinoma metastasis in the bladder mimicking as the second primary of urinary bladder on 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG PET/CT). The presentations of bladder lesions on 18F-FDG PET/CT are varied, and rare presentations of common malignancies can pose a significant diagnostic challenge as in the index case and highlight the importance of histopathological examination to confirm any unusual FDG uptake confounding the diagnosis.
Full text 4,241 characters · extracted from pmc-nxml · 2 sections · click to expand

Cases

A 69-year-old female presented with a 3-month history of painless vaginal bleeding. Initial pelvic ultrasonography revealed hypoechoic lesions (likely fibroids) in the anterior and posterior walls of the body of the uterus and additional lobulated hypoechoic lesions in the left lateral wall of the urinary bladder. A whole-body 18 F-fluorodeoxyglucose positron-emission tomography/computed tomography ( 18 F-FDG PET/CT) done for characterization and staging revealed intense tracer uptake in the heterogeneously enhancing soft-tissue lesion in the body and fundus of the uterus [Figure 1a - c ]. In addition, there were intensely FDG-avid heterogeneously enhancing soft-tissue lesions in the left posterolateral and posterior wall of the urinary bladder with one of them showing loss of fat planes with the uterine cervix giving the impression of second primary malignancy of urinary bladder with cervical infiltration [Figure 1d and e ]. Intense tracer uptake was also noted in few enlarged peripancreatic, mesenteric, precaval, aortocaval, retrocaval, and bilateral external iliac lymph nodes. With a provisional diagnosis of second malignancy in the urinary bladder, the patient underwent transurethral resection of bladder tumor (TURBT). However, histopathology revealed the presence of metastatic endometrioid adenocarcinoma [Figure 2a and b ]. 18 F-fluorodeoxyglucose positron-emission tomography/computed tomography showing intense fluorodeoxyglucose uptake in the heterogeneously enhancing soft-tissue lesion in the body and fundus of the uterus highlighted with arrow (Maximum intensity projection (MIP); a, axial fused positron-emission tomography computed tomography; b and axial computed tomography; c). fluorodeoxyglucose avid wall thickening in the left posterolateral wall of the urinary bladder (broken arrow in axial fused positron-emission tomography computed tomography; d and axial contrast-enhanced computed tomography; e) Low- (a) and high-power (b) photomicrographs from the transurethral resection of bladder tumor chips shows a complex glandular pattern lined by columnar cells with elongated vesicular nuclei with prominent nucleoli, consistent with a diagnosis of metastatic endometrioid carcinoma

Discussion

Endometrial carcinoma is a common malignancy of female genital tract with an increasing incidence in the postmenopausal women.[ 1 2 ] Local recurrence and distant metastases from advanced endometrial carcinoma, even after surgical resection, are known to occur in the pelvis, pelvic and paraaortic lymph nodes, peritoneum, and lungs. Supradiaphragmatic lymph nodes, liver, adrenals, brain, and soft tissues are the uncommon sites for metastases.[ 3 ] In advanced cases, it may rarely involve the bladder and bowel mucosa also.[ 4 ] Urinary bladder involvement in endometroid carcinoma is a rare entity resulting from direct extension, metastasis, or malignant transformation of endometriosis.[ 3 4 ] This case showcased a diagnostic conundrum of an endometrial neoplasm metastatic to the bladder giving an initial impression of a second primary urothelial malignancy on imaging. 18 F-FDG PET/CT is a very sensitive oncological imaging modality with ever-increasing role in genitourinary malignancies. The unusual presentations have been recognized with improved imaging. Few of imaging limitations and pitfalls are encountered, and some of them had been addressed.[ 5 6 7 ] However, in the index case, subsequent TURBT and histopathological examination revealed the features of nonurological endometroid adenocarcinoma. Thus, this case emphasizes the diagnostic challenges posed by rare presentations of certain malignancies on 18 F-FDG PET/CT and the importance of histopathological examination to ascertain the accurate diagnosis and management in such cases. The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Nil. There are no conflicts of interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
pubmed
last seen: 2026-10-08T21:24:24.182414+00:00
unpaywall
last seen: 2026-05-21T05:10:58.409756+00:00
License: publisher-OA-unknown · commercial use NOT OK · attribution required